Four takeaways:
1. Preliminary and unaudited revenue for the fourth quarter is in the range of $27.7 million to $28.1 million.
2. Sinuva had a quarterly revenue of about $2.5 million.
3. Vensure initiated U.S. sales with revenue of approximately $300,000.
4. Cash, cash equivalents and restricted cash were expected to be approximately $105 million as of Dec. 31, 2020.
Intersect ENT’s full fourth-quarter report is expected March 9.
More articles on surgery centers:
California hospital temporarily converts ASC into ICU
Surgery Partners reports $1.86B in 2020 revenue: 11 things to know
Are surgical robots worth it for ASCs? 3 administrators weigh in
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
